Viking has long been viewed as a takeover target, given the positive data from early VK2735 trials. The company’s most recent ...

Viking Therapeutics, Inc. (VKTX) closed at $33.69 in the latest trading session, marking a +0.78% move from the prior day. The stock outperformed the S&P 500, which registered a daily gain of 0.53%.

FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.

Viking products are created as easily transportable vacation solutions. Focused solely on camping trailers since 1996, Viking employs a patent pending Glide-N-Lock bed system. In 2008, Viking became ...

The latest trading session saw Viking Therapeutics, Inc. (VKTX) ending at $32.87, denoting a +0.67% adjustment from its last day's close. The stock's performance was behind the S&P 500's daily ...

Viking Therapeutics Inc said on Tuesday its experimental drug met the main goal of a mid-stage trial to treat patients with a type of fatty liver disease, sending its shares about 6% higher in ...

JPMorgan has reset the valuation for Viking Therapeutics Inc. VKTX and Structure Therapeutics Inc. GPCR. Analyst Hardik Parikh cites several reasons for recovery, including pathways for strategic ...

Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX – Get Free Report) have been assigned a consensus rating of “Buy” from the thirteen brokerages that are presently covering the stock ...

NEW YORK, Jan. 2, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Viking Therapeutics, Inc. ("Viking" or the "Company") (NASDAQ: VKTX). Such investors are ...

Viking products are created as easily transportable vacation solutions. Focused solely on camping trailers since 1996, Viking employs a patent pending Glide-N-Lock bed system. In 2008, Viking became ...